Compliance & Validation — Not documented by Atlas
Ask the vendor: Which compliance certifications (HIPAA, 21 CFR Part 11, SOC 2, GxP) do you hold?
NVIDIA BioNeMo
NVIDIA's platform of biology and chemistry foundation models for protein structure, molecular generation, and virtual screening.
NVIDIA BioNeMo, from NVIDIA (headquartered in Santa Clara, California; NASDAQ: NVDA), is a platform of biology and chemistry foundation models and tooling for drug discovery — spanning protein structure prediction, molecular generation, and virtual screening — that teams run as AI infrastructure via NVIDIA's cloud and on-premise GPU stack. NVIDIA positions BioNeMo, and independent trade press describes it, as becoming core infrastructure for AI-driven discovery rather than a niche point tool. Reported pharma traction includes an Eli Lilly partnership announced in January 2026 (covering AI-driven drug discovery and physical-AI applications, reported at up to $1B) and a 2026 QIAGEN collaboration combining graph-based AI with curated bioinformatics knowledge. BioNeMo is a vertical drug-discovery product and is scored here as a normal vendor — distinct from NVIDIA's broader horizontal AI-infrastructure business. No GxP-specific compliance claim was documented for BioNeMo at profiling time.
- Headquarters
- Santa Clara, United States
- Deployment options
- cloud, on-premise
- Website
- https://www.nvidia.com/en-us/clara/bionemo/
- https://www.linkedin.com/company/nvidia
Categories
AI Use Cases
- Hit Identification & Lead Optimization
- Target Identification & Validation
Vendor Scorecard
79% — Complete coverage. Coverage score — how completely Atlas documents NVIDIA BioNeMo across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.
Deployment & Hosting — Documented
cloud, on premise
Pricing Transparency — Documented
Platform / GPU based
Implementation & Onboarding — Documented
6–12 months
Organization & Role Fit — Documented
Mid-Size Biotech, Large Pharma, Top 20 Pharma, Drug Discovery, R&D Leadership, IT / Digital, Data Management
Solution Scope — Documented
Molecular Generation, Protein Structure Prediction, Target Identification
Company Viability — Partially documented
Public
Always ask the vendor
Not captured in Atlas data — confirm directly. Excluded from the score above.
Data Rights & IP
Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?
Model Credibility & Explainability
Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?
Questions to Ask This Vendor
- Which BioNeMo foundation models are validated for our target classes and modalities?
- What GPU infrastructure (cloud or on-premise) is required to run the models at our scale?
- How is proprietary sequence and structure data protected across the platform?
- What support and MLOps tooling exist for deploying and maintaining models in production?